文献速递肝病消化道肿瘤与早癌消化内镜

细胞外与肝胆特异性MR对比剂诊断小HCC的头对头比较

Comparison of extracellular and hepatobiliary MR contrast agents for the diagnosis of small HCCs.
PubMed 文献 · J Hepatol · 2019-12-21

多中心纳入171例肝硬化患者共225个1-3 cm结节,均行ECA-MRI与HBA-MRI头对头比较,以复合算法为金标准。两种方法敏感度相似,但HBA-MRI特异度低于ECA-MRI;1-2 cm结节中HBA-MRI特异度降至66.1%,而ECA-MRI为85.7%。

要点

  • HBA-MRI诊断小HCC的敏感度与ECA-MRI相似,但特异度更低。
  • 1-2 cm结节中HBA-MRI特异度66.1%,显著低于ECA-MRI的85.7%。
  • 国际指南推荐的HBA-MRI用于小HCC无创诊断时应谨慎。

核心结论

  • 在肝硬化患者中,HBA-MRI诊断小HCC的特异度低于ECA-MRI。
  • 该结果对HBA-MRI在小HCC无创诊断算法中的恰当使用提出疑问。

研究设计与样本

  • 多中心头对头结节比较研究,2014年8月至2017年10月共纳入171例肝硬化患者,每例1-3个1-3 cm结节。
  • 所有患者均在一个月内完成ECA-MRI和HBA-MRI检查。
  • 金标准采用既往发表的复合算法。

主要发现

  • 共纳入225个结节,其中153个为HCC,72个非HCC。
  • 两种MRI技术敏感度相似。
  • 特异度:ECA-MRI为83.3%(95% CI 72.7-91.1),HBA-MRI为68.1%(95% CI 56.0-78.6)。
  • ECA-MRI诊断HCC时,138个结节有APHE,84个在PVP洗脱,104个在DP洗脱。
  • HBA-MRI诊断HCC时,128个结节有APHE,71个在PVP洗脱,99个在HBP洗脱。

关键数值与推荐

  • ECA-MRI无创诊断HCC标准:动脉期高强化(APHE)伴门静脉期(PVP)和/或延迟期(DP)洗脱。
  • HBA-MRI无创诊断HCC标准:APHE伴PVP和/或肝胆期(HBP)洗脱。

临床怎么用

  • 在肝硬化患者小HCC无创诊断中,需关注HBA-MRI特异度低于ECA-MRI,尤其1-2 cm结节。
  • 尽管国际指南详细描述了HBA-MRI,用于小HCC无创诊断时应谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: The aim of this study was to use a head-to-head nodule comparison to compare the performance of extracellular contrast agent MRI (ECA-MRI) with that of hepatobiliary contrast agent MRI (HBA-MRI) for the non-invasive diagnosis of small hepatocellular carcinomas (HCCs). METHODS: Between August 2014 and October 2017, 171 patients with cirrhosis, each with 1 to 3 nodules measuring 1-3 cm, were enrolled across 8 centers. All patients underwent both an ECA-MRI and an HBA-MRI within a month. A non-invasive diagnosis of HCC was made when a nodule exhibited arterial phase hyper-enhancement (APHE) with washout at the portal venous phase (PVP) and/or delayed phase (DP) for ECA-MRI, or the PVP and/or HB phase (HBP) for HBA-MRI. The gold standard was defined by using a previously published composite algorithm. RESULTS: A total of 225 nodules, of which 153 were HCCs and 72 were not, were included. The sensitivites of both MRI techniques were similar. Specificity was 83.3% (95% CI 72.7-91.1) for ECA-MRI and 68.1% (95% CI 56.0-78.6) for HBA-MRI. In terms of HCC diagnosis on ECA-MRI, 138 nodules had APHE, 84 had washout at PVP, and 104 at DP; on HBA-MRI, 128 nodules had APHE, 71 had washout at PVP, and 99 at HBP. For nodules 2-3 cm in size, sensitivity and specificity were similar between the 2 approaches. For nodules 1-2 cm in size, specificity dropped to 66.1% (95% CI 52.2-78.2) for HBA-MRI vs. 85.7% (95% CI 73.8-93.6) for ECA-MRI. CONCLUSIONS: HBA-MRI specificity is lower than that of ECA-MRI for diagnosing small HCCs in patients with cirrhosis. These results raise the question of the proper use of HBA-MRI in algorithms for the non-invasive diagnosis of small HCCs. LAY SUMMARY: There are 2 magnetic resonance imaging (MRI)-based approaches available for the non-invasive diagnosis of hepatocellular carcinoma (HCC), using either extracellular or hepatobiliary contrast agents. The current results showed that the sensitivity of MRI with hepatobiliary contrast agents was similar to that with extracellular contrast agents, but the specificity was lower. Thus, hepatobiliary contrast agent-based MRI, although detailed in international guidelines, should be used with caution for the non-invasive diagnosis of HCC. CLINICAL TRIAL NUMBER: NCT00848952.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Paisant A, Vilgrain V, Riou J, et al. Comparison of extracellular and hepatobiliary MR contrast agents for the diagnosis of small HCCs. J Hepatol. 2019. PMID: 31870951. doi:10.1016/j.jhep.2019.12.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。